Filing Flows › AstraZeneca (AZN) › Q1 2025
AstraZeneca (AZN) Q1 2025 earnings results (first quarter 2025)
6-K filed Apr 29, 2025
AstraZeneca (AZN) reported revenue of $13.6B for the first quarter 2025 (Q1 2025), +7% from a year earlier. Operating margin was 27.0%, net earnings $2.9B (21.5% of revenue).
AstraZeneca, Q1 2025: revenue $13.6B (+7% year over year), operating margin 27.0%, net earnings $2.9B, operating cash flow $4.5B. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.6B | — | +7% |
| Gross profit | $11.3B | — | +8% |
| Operating profit | $3.7B | — | +18% |
| Net earnings | $2.9B | — | +34% |
| Operating cash flow | $4.5B | — | +38% |
| Free cash flow | $4.1B | — | +43% |
What changed
Revenue was $13.6B in Q1 2025, up 7% year over year. Oncology was the largest line at 42% of revenue.
Gross margin was 83.5%, up 1.0 points from a year earlier. Operating profit was $3.7B, a 27.0% margin (up 2.5 points year over year). Of the extra revenue versus a year earlier, 61% reached operating profit, above the 25% margin then. Operating expenses grew 4% against revenue growth of 7%. Net earnings were $2.9B, up 34% year over year. The effective tax rate was 14.1%.
Operating cash flow was $4.5B (up 38% year over year), 154% of net earnings. Working capital and other items added $1.6B. Capital expenditures of $0.43B left free cash flow of $4.1B.
Questions
What was AstraZeneca's revenue in the first quarter 2025?
AstraZeneca (AZN) reported revenue of $13.6B for the first quarter 2025 (Q1 2025), +7% from a year earlier.
Was AstraZeneca profitable in the first quarter 2025?
Operating profit was $3.7B (27.0% of revenue) and net earnings $2.9B.
Source: AstraZeneca 6-K on SEC EDGAR.